T cell receptor–major histocompatibility complex–antigen complex (TCR–MHC–antigen complex)

The **T cell receptor–major histocompatibility complex–antigen complex** (TCR–MHC–antigen complex) is a multi-component molecular assembly formed when a T cell receptor (TCR) on a T lymphocyte binds to a specific peptide antigen presented by a major histocompatibility complex (MHC) molecule on an antigen-presenting cell or target cell. Recognition of this complex is fundamental to the adaptive immune response: it determines the specificity of T cell–mediated immunity by enabling T cells to distinguish 'self' from 'non-self' antigens[1][5][7][9]. The TCR–MHC–antigen interaction both triggers intracellular signaling via the CD3 complex and co-receptors (CD4 or CD8), leading to T cell activation, clonal expansion, and effector functions such as cytotoxicity and cytokine secretion[3][8]. This molecular interface is highly polymorphic and specific, involving precise contacts between the variable domains of the TCR and both the antigenic peptide and the MHC molecule[2][4][5][9]. While the complex itself is not a single molecular target, it is central to numerous therapeutic strategies, especially in cancer immunotherapy and autoimmune disease—these approaches often aim to modulate, mimic, or engineer the recognition of peptide–MHC complexes by TCRs[6]. **Note**: This entry refers to a molecular complex rather than a single protein or classical therapeutic "target." For structured databases, it is best to describe individual components (e.g., "T cell receptor alpha chain," "major histocompatibility complex class I") separately.

Other names

TCR–pMHC complexTCR–peptide–MHC complexT cell receptor–peptide–MHC complex

Antigen-specific T cell activation via TCR–pMHC recognition; Cytotoxic T lymphocyte-mediated killing (via TCR engagement); Modulation of T cell activation thresholds (via engineered TCR or MHC molecules); Induction of T cell proliferation and cytokine secretion